当前位置:首页 > 报告详情

ELAN-JPM-2026-Presentation.pdf

上传人: 明**** 编号:1069839 2026-01-17 31页 2.93MB

1、J.P.Morgan Healthcare ConferenceJeff SimmonsPresident&CEOJanuary 13,2026Notices and DisclaimersForward-Looking Statements.This presentation contains forward-looking statements within the meaning of the federal securities laws,including,without limitation,statements concerning product launches and re

2、venue from such products,our 2025 full year and fourth quarter guidance,long-term expectations,our expectations regarding debt levels,and expectations regarding our industry and our operations,performance and financial condition,and including,in particular,statements relating to our business,growth

3、strategies,distribution strategies,product development efforts and future expenses.Forward-looking statements are based on our current expectations and assumptions regarding our business,the economy and other future conditions.Because forward-looking statements relate to the future,by their nature,t

4、hey are subject to inherent uncertainties,risks and changes in circumstances that are difficult to predict.As a result,our actual results may differ materially from those contemplated by the forward-looking statements.Important risk factors that could cause actual results to differ materially from t

5、hose in the forward-looking statements include regional,national or global political,economic,business,competitive,market and regulatory conditions,including but not limited to the following:operating in a highly competitive industry;the success of our research and development(R&D),regulatory approv

6、al and licensing efforts;the impact of disruptive innovations and advances in veterinary medical practices,animal health technologies and alternatives to animal-derived protein;competition from generic products that may be viewed as more cost-effective;changes in regulatory restrictions on the use o

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
1. **战略转型与增长目标**:Elanco通过创新、产品组合和生产力战略,实现可持续股东价值,目标2026年创新收入超$1.1B,2026-2028年自由现金流超$1B,净杠杆率2027年降至<3x,长期目标2.0x-2.5x。 2. **创新引擎与产品管线**:2025年创新收入预期$840-$880M,2026年“Big 6”产品驱动$1.1B收入;2026-2031年预计5-6款重磅产品获批,峰值销售潜力>$2B,覆盖寄生虫、皮肤科、可持续性等领域。 3. **财务优化与效率提升**:通过“Elanco Ascend”计划,2030年调整后EBITDA节省$200-$250M,2025年调整后EBITDA率扩张200-350bps,2024年净杠杆率降至4.3x。 4. **行业优势与市场地位**:全球动物健康市场从$420B增至$600B,Elanco在宠物健康(零售第一、兽医增长第一)和农场动物(全球第二)领域领先,拥有70年历史和90+国家覆盖。
**创新引擎如何驱动增长?** **财务目标能否实现?** **行业趋势有何影响?**
客服
商务合作
小程序
服务号
折叠